Art. -Nr.: HY-120548

KBU2046

Kundenbewertung

Based on 1 Customer Validation

KBU2046 is an orally active transforming growth factor-β (TGF-β1) inhibitor. KBU2046 reduces integrin family protein expression, decreases Raf, RIPK1 and ERK phosphorylation to deactivate the ERK signaling pathway, and down-regulates genes linked to TGF-β1 maturation. KBU2046 suppresses tumor cell motility, impedes cancer invasion and metastasis, and inhibits human ESCC growth and metastasis in a murine model. KBU2046 can be used for the researches of triple-negative breast cancer and esophageal squamous cell carcinoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.85%
CAS. Nr.: 1143863-69-7
Formel: C₁₅H₁₁FO₂
Molecular Weight:242.25

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

KBU2046 Chemical Structure

CAS. Nr.: 1143863-69-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

RIPK1

ERK1

ERK2

Alle TGF-β Receptor Isoform-spezifische Produkte anzeigen :

Alle Integrin Isoform-spezifische Produkte anzeigen :

Alle Raf Isoform-spezifische Produkte anzeigen :

Alle RIP kinase Isoform-spezifische Produkte anzeigen :

Alle ERK Isoform-spezifische Produkte anzeigen :

In Vitro

KBU2046 (1-10 μM; 24-48 h) does not significantly alter the proliferation of MDA-MB-231 or BT-549 TNBC cells^[1].
KBU2046 (1-10 μM; 24 h) dose-dependently inhibits TGF-β1-induced motility of MDA-MB-231 and BT-549 TNBC cells, with maximum inhibition at 10 μM, reducing motility to 50.77% and 36.09% of control levels, respectively^[1].
KBU2046 (10 μM; 24 h) significantly down-regulates the mRNA expression of LRRC8E, LTBP3, DNAL1, and MAFF in MDA-MB-231 and BT-549 TNBC cells^[1].
KBU2046 (1-10 μM; 48 h) dose-dependently suppresses integrin αv and integrin α6 protein expression in MDA-MB-231 and BT-549 TNBC cells, and reverses TGF-β1-mediated up-regulation of these integrins^[1].
KBU2046 (10 μM; 15-60 min) time-dependently inhibits phosphorylation of Raf1 and ERK1/2 in MDA-MB-231 and BT-549 TNBC cells, with significant suppression evident within 15 min of treatment^[1].
KBU2046 (1-10 μM; 24-48 h) inhibits collective migration of KYSE-30 and KYSE-410 ESCC cells in a time- and concentration-dependent manner^[2].
KBU2046 (10 μM; 72 h) inhibits EGF and TGF-β-stimulated single-cell migration and invasion of KYSE-30 and KYSE-410 ESCC cells^[2].
KBU2046 (1-10 μM; 72 h) does not inhibit proliferation of KYSE-30 or KYSE-410 ESCC cells after 72-hour incubation^[2].
KBU2046 (10 μM; 30 min) inhibits EGF-stimulated phosphorylation of RIPK1 at Ser166 in KYSE-30 and KYSE-410 ESCC cells^[2].
KBU2046 (1-10 μM) downregulates ITGA3, ITGA6, and ITGAV expression in KYSE-30 and KYSE-410 ESCC cells in a concentration-dependent manner^[2].
KBU2046 (10 μM) selectively modulates expression of motility-related proteins in KYSE-30 ESCC cells, with significant downregulation of integrin family members and other ECM-adhesion proteins that are overexpressed in human ESCC^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

MDA-MB-231, BT-549 cells
Concentration:

1, 5, 10 μM
Incubation Time:

24 h; 48 h;
Result:

Exhibited no time- or concentration-dependent alterations in cell proliferation in either MDA-MB-231 or BT-549 cells.

Cell Migration Assay ^[1]

Cell Line:

MDA-MB-231, BT-549 cells
Concentration:

1, 5, 10 μM
Incubation Time:

24 h
Result:

Reduced TGF-β1-induced cellular motility rates to 92.97% at 1 μM, 70.59% at 5 μM, and 50.77% at 10 μM in MDA-MB-231 cells compared to control.
Reduced TGF-β1-induced cellular motility rates to 78.43% at 1 μM, 43.55% at 5 μM, and 36.09% at 10 μM in BT-549 cells compared to control.

Western Blot Analysis^[1]

Cell Line:

MDA-MB-231, BT-549 cells
Concentration:

1, 5, 10 μM
Incubation Time:

48 h (co-treatment with 10 ng/mL TGF-β1)
Result:

Reduced integrin αv protein levels to 67.28% at 1 μM, 57.61% at 5 μM, and 42.29% at 10 μM, and integrin α6 levels to 87.15% at 1 μM, 76.54% at 5 μM, and 45.26% at 10 μM in MDA-MB-231 cells compared to control.
Reduced integrin αv levels to 96.13% at 1 μM, 58.68% at 5 μM, and 51.11% at 10 μM, and integrin α6 levels to 82.47% at 1 μM, 66.29% at 5 μM, and 61.89% at 10 μM in BT-549 cells compared to control.
Partially reversed TGF-β1-mediated up-regulation of integrin αv and α6 in both cell lines.
Exhibited no significant effects on integrin α3 or β8 protein levels.

Western Blot Analysis^[1]

Cell Line:

MDA-MB-231, BT-549 cells
Concentration:

10 μM
Incubation Time:

15 min; 30 min; 60 min
Result:

Reduced phosphorylation levels of Raf1 (Ser338) and ERK1/2 (Thr202/Tyr204) in a time-dependent manner in both MDA-MB-231 and BT-549 cells.
Showed statistically significant reductions at 15, 30, and 60 min compared to control levels.

Cell Migration Assay^[2]

Cell Line:

KYSE-30, KYSE-410 esophageal squamous cell carcinoma (ESCC) cells
Concentration:

1 μM, 10 μM
Incubation Time:

24 h, 48 h
Result:

Significantly inhibited wound gap closure in a time- and concentration-dependent manner.
Decreased wound closure by 46.7% in KYSE-30 cells and 47.5% in KYSE-410 cells at 48 h with 10 μM treatment compared to vehicle controls.

Cell Proliferation Assay^[2]

Cell Line:

KYSE-30, KYSE-410 esophageal squamous cell carcinoma (ESCC) cells
Concentration:

1 μM, 10 μM
Incubation Time:

72 h
Result:

Had no significant effect on cell viability of KYSE-30 or KYSE-410 cells after 72 h, indicating no inhibition of cell proliferation.

Western Blot Analysis^[2]

Cell Line:

EGF-stimulated KYSE-30, KYSE-410 esophageal squamous cell carcinoma (ESCC) cells
Concentration:

10 μM (in the presence of 5 ng/mL EGF)
Incubation Time:

30 min
Result:

Markedly inhibited EGF-stimulated phosphorylation of RIPK1 at Ser166 in both KYSE-30 and KYSE-410 cells.

In Vivo

KBU2046 (80 mg/kg; i.g.; every other day; 12 total doses) completely inhibits pulmonary metastasis of ESCC cells in male NOD-SCID mice^[2].
KBU2046 (80 mg/kg; i.g.; every 2 days; 12 total doses) reduces mean ESCC tumor volume to 62% of control levels in male athymic nude mice, without causing significant systemic toxicity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOD-SCID (male, 4-6 weeks old, 16-18 g, tail vein injection of 1.5×10⁶ KYSE-30 ESCC cells)^[2]
Dosage:

80 mg/kg
Administration:

p.o.; every other day; 12 total doses
Result:

Completely inhibited pulmonary metastasis, with 0 of 4 treated mice showing pulmonary metastases compared to 3 of 4 control mice (one-sided t-test, P=0.03).
Showed no significant difference in body weight compared to control group.
Caused no histomorphological changes in heart, liver, or spleen.

Animal Model:

athymic nude (male, 4-6 weeks old, SPF grade, subcutaneous implantation of 1×10⁶ KYSE-30 ESCC cells into the right flank)^[2]
Dosage:

80 mg/kg
Administration:

p.o.; every 2 days; 12 total doses
Result:

Reduced mean tumor volume to 62% of control levels, though the difference was not statistically significant.
Showed no significant difference in body weight compared to control group.

Chemical Information

CAS. Nr. 1143863-69-7
Appearance Solid
Molecular Weight 242.25
Formel C₁₅H₁₁FO₂
Color White to off-white
SMILES

O=C1C(C2=CC=C(F)C=C2)COC3=CC=CC=C13
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (206.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.1280 mL

20.6398 mL

41.2797 mL

5 mM

0.8256 mL

4.1280 mL

8.2559 mL

10 mM

0.4128 mL

2.0640 mL

4.1280 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Chen J, et al. Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation in vitro. Oncol Res. 2024;32(11):1791-1802. Published 2024 Oct 16. [Content Brief]

[2]. Li K, et al. KBU2046 exerts inhibition on chemokine gradient-mediated motility of esophageal squamous cell carcinoma through reducing integrin expression. Biochim Biophys Acta Mol Basis Dis. 2025;1871(5):167800. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.1280 mL	20.6398 mL	41.2797 mL	103.1992 mL
	5 mM	0.8256 mL	4.1280 mL	8.2559 mL	20.6398 mL
	10 mM	0.4128 mL	2.0640 mL	4.1280 mL	10.3199 mL
	15 mM	0.2752 mL	1.3760 mL	2.7520 mL	6.8799 mL
	20 mM	0.2064 mL	1.0320 mL	2.0640 mL	5.1600 mL
	25 mM	0.1651 mL	0.8256 mL	1.6512 mL	4.1280 mL
	30 mM	0.1376 mL	0.6880 mL	1.3760 mL	3.4400 mL
	40 mM	0.1032 mL	0.5160 mL	1.0320 mL	2.5800 mL
	50 mM	0.0826 mL	0.4128 mL	0.8256 mL	2.0640 mL
	60 mM	0.0688 mL	0.3440 mL	0.6880 mL	1.7200 mL
	80 mM	0.0516 mL	0.2580 mL	0.5160 mL	1.2900 mL
	100 mM	0.0413 mL	0.2064 mL	0.4128 mL	1.0320 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

KBU2046

Apoptosis Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Angiogenesis-Related Compound Library

Osteogenesis Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Extracellular Vesicles (EVs) Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Alle TGF-β Receptor Isoform-spezifische Produkte anzeigen

Alle Integrin Isoform-spezifische Produkte anzeigen

Alle Raf Isoform-spezifische Produkte anzeigen

Alle RIP kinase Isoform-spezifische Produkte anzeigen

Alle ERK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

KBU2046 Related Classifications

HY-120548 Related Classifications